Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
112.70
+0.70 (0.63%)
Oct 30, 2024, 11:08 AM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 68.06B DKK in the quarter ending June 30, 2024, with 25.34% growth. This brings the company's revenue in the last twelve months to 258.00B, up 28.15% year-over-year. In the year 2023, Novo Nordisk had annual revenue of 232.26B with 31.26% growth.
Revenue (ttm)
258.00B DKK
Revenue Growth
+28.15%
P/S Ratio
n/a
Revenue / Employee
4.01M DKK
Employees
64,319
Market Cap
497.77B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 920.97M |
Vireo Growth Inc. | 98.04M |
Medexus Pharmaceuticals Inc. | 108.78M |
Novo Nordisk News
- 15 hours ago - Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says - CNBC
- 19 hours ago - US FDA says lowest dose of Novo Nordisk's weight-loss drug now available - Reuters
- 23 hours ago - Eli Lilly stock tumbles 10% after missing estimates and slashing profit guidance - CNBC
- 2 days ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 2 days ago - Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates - Business Wire
- 3 days ago - Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? - The Motley Fool
- 4 days ago - This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic) - The Motley Fool
- 6 days ago - Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows - Benzinga